BioSpace News Archive

Drug Development

Roche, Exelixis’ Drug Combo Bounces Back with Late-Stage Prostate Cancer Win

After sustaining two Phase III fails, Roche and Exelixis finally reported a late-stage win for their combination regimen of Tecentriq and Cabometyx in metastatic castration-resistant prostate cancer.

August 21, 2023
·
2 min read
·
Tristan Manalac
Job Trends

Report: Benchmarking Paid Time Off Policies

BioSpace is exploring PTO trends and federal holidays granted to life sciences professionals.

August 21, 2023
·
1 min read
·
BioSpace Insights
Employer Resources

Report: Recruitment Market Update, 2023 Q2

Following a tumultuous start to 2023, layoffs have cooled off though recruiting activities have been significantly impacted by the economic environment.

August 21, 2023
·
1 min read
·
BioSpace Insights
Business

Moderna, CARsgen Join Forces Combining mRNA Cancer Vaccine with CAR T

The companies will evaluate Moderna’s investigational Claudin18.2 mRNA cancer vaccine in combination with CARsgen’s Claudin18.2 CAR T cell candidate.

August 21, 2023
·
2 min read
·
Greg Slabodkin
Job Trends

Report: 2023 U.S. Life Sciences Salary Trends

BioSpace’s annual Salary Report explores the average salaries and salary trends of life sciences professionals.

August 21, 2023
·
1 min read
·
BioSpace Insights
FDA

Regeneron Expands Eylea’s Label with High-Dose Approval

Following a prior rejection due to manufacturing problems, Regeneron’s higher-dose Eylea won the FDA’s approval Friday, allowing for more infrequent dosing for the treatment of various eye diseases.

August 21, 2023
·
2 min read
·
Tristan Manalac
Drug Development

Gilead’s Magrolimab Again Placed on Partial Clinical Hold by FDA

The biopharma’s acute myeloid leukemia hopeful is on partial clinical hold, affecting two Phase III AML studies, Gilead announced Monday. The CD47 candidate also spent four months on hold in 2022.

August 21, 2023
·
2 min read
·
Matt Olszewski
Employer Resources

Report: Supporting Employee Resource Groups

BioSpace has created guidelines on how biopharma organizations, large and small, can effectively support employee resource groups (ERGs), encouraging both their creation and ongoing participation.

August 21, 2023
·
1 min read
·
BioSpace Insights
Employer Resources

Report: Recruitment Market Update, 2023 Q1

Economic turbulence has persisted into 2023 and the life science industry is certainly not immune. How are organizations juggling business needs, budgets, recruitment and retention?

August 21, 2023
·
1 min read
·
BioSpace Insights
The Biopharma Patent Cliff: 9 Drugs Losing Exclusivity by the End of 2023

Many products are facing the loss of their patents or exclusivity clauses. Here’s what to expect in the coming months.

August 21, 2023
·
6 min read
·
Nadia Bey